Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.
本发明涉及选择性抑制细胞色素P-450 2A6(CYP2A6)的
尼古丁相关化合物,选择性抑制细胞色素P-450 2A13(CYP2A13),和/或选择性调节
尼古丁乙酰胆碱受体(nAChR)。本发明还涉及包含本发明化合物的制药组合物,以及使用该制药组合物治疗或预防与
尼古丁摄入有关的疾病或障碍,或者通过选择性调节nAChRs进行治疗的疾病或障碍的方法。